Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching-Reference-Cited by-同舟云学术

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

Published:2018-01-24 Issue:1 Volume:13 Page:e0191239
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chamorro Virginia,Morales-Cano Daniel,Milara Javier,Barreira Bianca,Moreno Laura,Callejo María,Mondejar-Parreño Gema,Esquivel-Ruiz Sergio,Cortijo Julio,Cogolludo Ángel,Barberá Joan A.,Perez-Vizcaino Francisco^ORCID

Funder

Secretaría de Estado de Investigación, Desarrollo e Innovación

Ministerio de Economía y Competitividad

Instituto de Salud Carlos III

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);N Galie;Eur Respir J,2015

2. Relevant issues in the pathology and pathobiology of pulmonary hypertension;RM Tuder;J Am Coll Cardiol,2013

3. Molecular pathogenesis of pulmonary arterial hypertension;M Rabinovitch;J Clin Invest,2012

4. Riociguat for the treatment of pulmonary arterial hypertension;HA Ghofrani;N Engl J Med,2013

5. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation;G Thabut;Chest,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase;European Respiratory Review;2024-01-31

2. Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease;Respiratory Investigation;2024-01

3. The small‐molecule formyl peptide receptor biased agonist, compound 17b, is a vasodilator and anti‐inflammatory in mouse precision‐cut lung slices;British Journal of Pharmacology;2023-09-26

4. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide;Frontiers in Pediatrics;2022-12-01

5. Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review;Biomedicine & Pharmacotherapy;2022-02